ELEVATE-RR: Acalabrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Use of epcoritamab resulted in an encouraging rate of complete remission and undetectable minimal residual disease in a small study of heavily pretreated R/R CLL.

CAR-T therapy may offer durable disease control and a potential path to cure for some patients with relapsed/refractory CLL, according to new long-term data.

Acalabrutinib plus venetoclax, with or without obinutuzumab, improves PFS in patients with untreated CLL compared with chemoimmunotherapy, new data show.

A survey of community-based cancer providers indicated that many have developed practices to address challenges in initiating venetoclax for patients with CLL.

ASH leaders outlined key clinical research on blood cancers and themes that will be featured during the 2024 annual meeting. Here’s what to watch for this year.

The FDA approved an updated label for fludarabine phosphate, which includes changes to indications, warnings and precautions, recommended dosages, and more.

Only a small percentage of patients with CLL treated with venetoclax experienced tumor lysis syndrome, a recent real-world, single-center study showed.

Vitamin D supplementation was tied to significantly longer treatment-free survival in patients with asymptomatic CLL under active surveillance, new data show.

Daniel A. Ermann, MD, and Robert A. Figlin, MD, discuss how two new FDA approvals in CLL set up “a difficult choice” and what to consider when deciding.

Early data on new agents and clarifying insights into the use of CAR-T therapy were among the highlights in CLL research at EHA 2024, says Adam Kittai, MD.

TP53 mutation status is a commonly used biomarker for high-risk disease in chronic lymphocytic leukemia, but some variants may be less dangerous than others.

Long-term follow-up data from the CAPTIVATE study show continued PFS benefit with fixed-duration ibrutinib plus venetoclax in high-risk patients with CLL.